慢性丙型肝炎直接抗病毒药物应用现状及存在问题

张熙; 李用国

doi:10.3969/j.issn.1001-5256.2018.04.034

慢性丙型肝炎直接抗病毒药物应用现状及存在问题

DOI: 10.3969/j.issn.1001-5256.2018.04.034

张熙,
李用国

哈尔滨医科大学附属第一医院感染科

详细信息

中图分类号: R512.63
计量
- 文章访问数: 1956
- HTML全文浏览量: 16
- PDF下载量: 439
- 被引次数: 0
出版历程
- 收稿日期: 2017-11-06
- 出版日期: 2018-04-20

Current status of the application of direct-acting antiviral agents in treatment of chronic hepatitis C and existing problems

Department of Infectious Diseases, The First Affiliated Hospital of Harbin Medical University

摘要

摘要: 慢性丙型肝炎可导致肝硬化、肝细胞癌等终末期肝病的发生,及时抗病毒治疗是改善预后的关键。直接抗病毒药物(DAAs)的诞生及发展使慢性丙型肝炎治疗发生了划时代的改变。当下世界各国正逐渐或已经步入DAAs时代,我国DAAs获批上市较晚,药物应用于临床时间短,临床数据有限。主要从国外相关研究出发,对适合我国患者的DAAs代表药物、治疗方案及存在的问题进行综述。
- 肝炎,丙型,慢性 /
- 抗病毒药 /
- 治疗 /
- 综述
Abstract: Chronic hepatitis C can lead to end-stage liver diseases such as liver cirrhosis and hepatocellular carcinoma, and timely antiviral therapy is the key to improving prognosis.The emergence and development of direct-acting antiviral agents (DAAs) have brought great changes to the treatment of chronic hepatitis C.Nowadays the countries in the world are gradually entering or have entered the era of DAAs, and the approval of the DAAs in our country is late, which leads to a short time of clinical application and limited clinical data.With reference to the studies in foreign countries, this article reviews the representative DAAs and treatment regimens which are suitable for Chinese patients and discusses some existing problems.
- hepatitis C, chronic /
- antiviral agents /
- therapy /
- review

HTML全文

参考文献(48)

[1]LI G, de CLERCP E.Current therapy for chronic hepatitis C:the role of direct-acting antivirals[J].Antiviral Res, 2017, 142:83-122.

[2]KIRBY BJ, SYMONDS WT, KEARNEY BP, et al.Pharmacokinetic, pharmacodynamic, and druginteraction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir[J].Clin Pharmacokinet, 2015, 54 (7) :677-690.

[3]MESSINA JP, HUMPHREYS I, FLAXMAN A, et al.Global distribution and prevalence of hepatitis C virus genotypes[J].Hepatology, 2015, 61 (1) :77-87.

[4]RAO H, WEI L, LOPEZ-TALAVERA JC, et al.Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection[J].J Gastroenterol Hepatol, 2014, 29 (3) :545-553.

[5]KEATING GM.Daclatasvir:a review in chronic hepatitis C[J].Drugs, 2016, 76 (14) :1381-1391.

[6]ALAVIAN SM, REZAEE-ZAVAREH MS.Daclatasvir-based treatment regimens for hepatitis C virus infection:a systematic review and meta-analysis[J].Hepat Mon, 2016, 16 (9) :e41077.

[7]WELZEL TM, PETERSEN J, HERZER K, et al.Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort[J].Gut, 2016, 65 (11) :1861-1870.

[8]NELSON DR, COOPER JN, LALEZARI JP, et al.All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection:ALLY-3 phase III study[J].Hepatology, 2015, 61 (4) :1127-1135.

[9]LEROY V, ANGUS P, BRONOWICKI JP, et al.Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease:a randomized phase III study (ALLY-3+) [J].Hepatology, 2016, 63 (5) :1430-1441.

[10]NKUIZE M, SERSTE T, BUSET M, et al.Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection:a review and clinical perspective[J].Ther Clin Risk Manag, 2016, 12:861-872.

[11]KOWDLEY KV, SUNDARAM V, JEON CY, et al.Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1hepatitis C virus infection[J].Hepatology, 2017, 65 (4) :1094-1103.

[12]GAMAL N, ANDREONE P.Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C[J].Expert Opin Drug Saf, 2016, 15 (4) :549-557.

[13] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.

[14]REDDY KR, BOURLIERE M, SULKOWSKI M, et al.Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis:an integrated safety and efficacy analysis[J].Hepatology, 2015, 62 (1) :79-86.

[15]STOKES W, FENTON C, CLEMENT F, et al.The efficacy and safety of 12 weeks of sofosbuvir and ledipasvir versus sofosbuvir, ledipasvir, and ribavirin in patients with chronic hepatitis C, genotype 1, who have cirrhosis and have failed prior therapy:a systematic review and meta-analysis[J].Can J Gastroenterol Hepatol, 2017, 2017:6468309.

[16]JI D, CHEN GF, WANG C, et al.Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients[J].Hepatol Int, 2016, 10 (5) :789-798.

[17]BALISTRERI WF, MURRAY KF, ROSENTHAL P, et al.The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection[J].Hepatology, 2017, 66 (2) :371-378.

[18]GREIG SL.Sofosbuvir/Velpatasvir:a review in chronic hepatitis C[J].Drugs, 2016, 76 (16) :1567-1578.

[19]FOSTER GR, AFDHAL N, ROBERTS SK, et al.Sofosbuvir and Velpatasvir for HCV genotype 2 and 3 infection[J].N Engl J Med, 2015, 373 (27) :2608-2617.

[20]FELD JJ, JACOBSON IM, HEZODE C, et al.Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection[J].N Engl J Med, 2015, 373 (27) :2599-2607.

[21]CURRY MP, O'LEARY JG, BZOWEJ N, et al.Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis[J].N Engl J Med, 2015, 373 (27) :2618-2628.

[22]EVERSON GT, TOWNER WJ, DAVIS MN, et al.Sofosbuvir with Velpatasvir in treatment-naive noncirrhotic patients with genotype1 to 6 hepatitis C virus infection:a randomized trial[J].Ann Intern Med, 2015, 163 (11) :818-826.

[23]WEISBERG IS, JACOBSON IM.A pangenotypic, single tablet regimen of Sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection[J].Expert Opin Pharmacother, 2017, 18 (5) :535-543.

[24]BERDEN FA, AALDERING BR, GROENEWOUD H, et al.Identification of the best direct-acting antiviral regimen for patients with hepatitis C virus genotype 3 infection:a systematic review and network meta-analysis[J].Clin Gastroenterol Hepatol, 2017, 15 (3) :349-359.

[25]BOURLIERE M, GORDON SC, FLAMM SL, et al.Sofosbuvir, Velpatasvir, and Voxilaprevir for previously treated HCV infection[J].N Engl J Med, 2017, 376 (22) :2134-2146.

[26]WEI L, ZHANG M, XU M, et al.A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfatherapies with or without ribavirin[J].J Gastroenterol Hepatol, 2016, 31 (11) :1860-1867.

[27]SARRAZIN C, ISAKOV V, SVAROVSKAIA ES, et al.Late relapse versus HCV reinfection in patients with sustained virologic response after sofosbuvir-based therapies[J].Clin Infect Dis, 2017, 64 (1) :44-52.

[28]van der MEER AJ, BERENGUER M.Reversion of disease manifestations after HCV eradication[J].J Hepatol, 2016, 65 (Suppl 1) :s95-s108.

[29]ZENG QL, XU GH, ZHANG JY, et al.Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C:a real-life observationalstudy[J].J Hepatol, 2017, 66 (6) :1123-1129.

[30]ROTMAN Y, NOUREDDIN M, FELD JJ, et al.Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C[J].Gut, 2014, 63 (1) :161-169.

[31]MIHM U, WELKER MW, TEUBER G, et al.Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection[J].J Viral Hepat, 2014, 21 (1) :42-52.

[32]CLARK V, NELSON DR.The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C[J].Liver Int, 2012, 32 (Suppl 1) :103-107.

[33]HEZODE C, BRONOWICKI JP.Ideal oral combinations to eradicate HCV:the role of ribavirin[J].J Hepatol, 2016, 64 (1) :215-225.

[34]DICK TB, LINDBERG LS, RAMIREZ DD, et al.A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection[J].Hepatology, 2016, 63 (2) :634-643.

[35]TALAVERA PONS S, BOYER A, LAMBLIN G, et al.Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C[J].Br J Clin Pharmacol, 2017, 83 (2) :269-293.

[36]ZHANG Y, LENG XJ, YAN XB.Interaction between anti-HCV direct anti-viral agents and other drugs[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition, 2017, 11 (2) :105-110. (in Chinese) 张莹, 冷雪君, 颜学兵.抗HCV直接抗病毒药与其他药物的相互作用[J/CD].中华实验和临床感染病杂志:电子版, 2017, 11 (2) :105-110.

[37]SARRAZIN C.The importance of resistance to direct antiviral drugs in HCV infection in clinical practice[J].J Hepatol, 2016, 64 (2) :486-504.

[38]PAWLOTSKY JM.Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens[J].Gastroenterology, 2016, 151 (1) :70-86.

[39]LI Z, CHEN ZW, REN H, et al.Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents[J].Chin J Hepatol, 2017, 25 (3) :170-174. (in Chinese) 李召, 陈志伟, 任红, 等.丙型肝炎直接抗病毒治疗耐药相关突变的临床意义[J].中华肝脏病杂志, 2017, 25 (3) :170-174.

[40]CONTI F, BUONFIGLIOLI F, SCUTERI A, et al.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals[J].J Hepatol, 2016, 65 (4) :727-733.

[41]REIG M, MARINO Z, PERELLO C, et al.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy[J].J Hepatol, 2016, 65 (4) :719-726.

[42]KOBAYASHI M, SUZUKI F, FUJIYAMA S, et al.Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection[J].J Med Virol, 2017, 89 (3) :476-483.

[43]NAGATA H, NAKAGAWA M, ASAHINA Y, et al.Effect of interferon-based and-free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C[J].J Hepatol, 2017, 67 (5) :933-939.

[44]HENGST J, FALK CS, SCHLAPHOFF V, et al.DAA-induced HCV clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C[J].J Infect Dis, 2016, 214 (12) :1965-1974.

[45]D'AMBROSIO R, COLOMBO M.Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression[J].Liver Int, 2016, 36 (6) :783-790.

[46]KAWAGISHI N, SUDA G, ONOZAWA M, et al.Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C[J].J Viral Hepat, 2017, 24 (12) :1098-1106.

[47]CHEN G, WANG C, CHEN J, et al.Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents:a systematic review and meta-analysis[J].Hepatology, 2017, 66 (1) :13-26.

[48]WANG C, JI D, CHEN J, et al.Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents[J].Clin Gastroenterol Hepatol, 2017, 15 (1) :132-136.

施引文献

资源附件(0)

访问统计